Expertise in
5
conditions

Tingyu R. Wang

Tianjin, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Tianjin, CN 

Overview

Tingyu Wang practices practicing medicine in Tianjin, China.

Wang is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 55 peer reviewed articles and participating in 2 clinical trials.

Locations

Tianjin, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: APG2575
Study Phase: Phase 2
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: ATG-010
Study Phase: Phase 2
View 1 Less Clinical Trial

55 Total Publications

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 27, 2026

Frequently Asked Questions about Tingyu R. Wang

Is Tingyu R. Wang a top-rated expert for Waldenstrom Macroglobulinemia?

MediFind is an objective health platform that identifies experts based on real-world data. Tingyu R. Wang is classified as an Advanced expert for Waldenstrom Macroglobulinemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tingyu R. Wang participate in research or clinical trials?

Yes. Tingyu R. Wang has published 55 articles and abstracts on conditions like Waldenstrom Macroglobulinemia. You can view a list of Tingyu R. Wang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wang's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile